Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer

被引:9
作者
Ma, Yang-Yang [1 ]
Leng, Yin [2 ]
Xing, Yan-Li [2 ]
Li, Hong-Mei [2 ]
Chen, Ji-Bing [1 ]
Niu, Li-Zhi [3 ]
机构
[1] Jinan Univ, Affiliated Fuda Canc Hosp, Cent Lab, Guangzhou 510665, Guangdong, Peoples R China
[2] Jinan Univ, Affiliated Fuda Canc Hosp, Dept Oncol, Guangzhou 510665, Guangdong, Peoples R China
[3] Jinan Univ, Affiliated Fuda Canc Hosp, Dept Intervent Radiol, 2 Tangde West Rd, Guangzhou 510665, Guangdong, Peoples R China
关键词
Irreversible electroporation; Gemcitabine; Locally advanced pancreatic cancer; Overall survival; Progression free survival; Prognostic factors; INDUCTION CHEMOTHERAPY; ABLATION; SAFETY; ADENOCARCINOMA; RADIOTHERAPY; SURVIVAL; DELIVERY;
D O I
10.12998/wjcc.v8.i22.5564
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Locally advanced pancreatic cancer (LAPC) is a common malignant digestive system tumor that ranks as the fourth leading cause of cancer-related death in the world. The prognosis of LAPC is poor even after standard treatment. Irreversible electroporation (IRE) is a novel ablative strategy for LAPC. Several studies have confirmed the safety of IRE. To date, no prospective studies have been performed to investigate the therapeutic efficacy of conventional gemcitabine (GEM) plus concurrent IRE. AIM To compare the therapeutic efficacy between conventional GEM plus concurrent IRE and GEM alone for LAPC. METHODS From February 2016 to September 2017, a total of 68 LAPC patients were treated with GEM plus concurrent IRE n = 33) or GEM alone n = 35). Overall survival (OS), progression free survival (PFS), and procedure-related complications were compared between the two groups. Multivariate analyses were performed to identify any prognostic factors. RESULTS There were no treatment-related deaths. The technical success rate of IRE ablation was 100%. The GEM + IRE group had a significantly longer OS from the time of diagnosis of LAPC (19.8 mo vs 9.3 mo, P < 0.0001) than the GEM alone group. The GEM + IRE group had a significantly longer PFS (8.3 mo vs 4.7 mo, P < 0.0001) than the GEM alone group. Tumor volume less than 37 cm(3) and GEM plus concurrent IRE were identified as significant favorable factors for both the OS and PFS. CONCLUSION Gemcitabine plus concurrent IRE is an effective treatment for patients with LAPC.
引用
收藏
页码:5564 / 5575
页数:12
相关论文
共 50 条
[21]   Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer [J].
Lafranceschina, Stefano ;
Brunetti, Oronzo ;
Delvecchio, Antonella ;
Conticchio, Maria ;
Ammendola, Michele ;
Curro, Giuseppe ;
Piardi, Tullio ;
de'Angelis, Nicola ;
Silvestris, Nicola ;
Memeo, Riccardo .
CANCERS, 2019, 11 (11)
[22]   Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation [J].
He, Chaobin ;
Wang, Jun ;
Zhang, Yu ;
Cai, Zhiyuan ;
Lin, Xiaojun ;
Li, Shengping .
CANCER MEDICINE, 2020, 9 (13) :4699-4710
[23]   Irreversible electroporation for locally advanced pancreatic cancer [J].
Tasu, J. -P. ;
Vesselle, G. ;
Herpe, G. ;
Richer, J. -P. ;
Boucecbi, S. ;
Velasco, S. ;
Carretier, M. ;
Debeane, B. ;
Tougeron, D. .
DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2016, 97 (12) :1297-1304
[24]   Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer [J].
Shinoto, Makoto ;
Yamada, Shigeru ;
Terashima, Kotaro ;
Yasuda, Shigeo ;
Shioyama, Yoshiyuki ;
Honda, Hiroshi ;
Kamada, Tadashi ;
Tsujii, Hirohiko ;
Saisho, Hiromitsu .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 95 (01) :498-504
[25]   Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer [J].
Zhao, Hong ;
Yang, Guowang ;
Wang, Daoyuan ;
Yu, Xiangrong ;
Zhang, Yu ;
Zhu, Junqiu ;
Ji, Yongle ;
Zhong, Baoliang ;
Zhao, Wenshuo ;
Yang, Zhong ;
Aziz, Fahad .
ANTI-CANCER DRUGS, 2010, 21 (04) :447-452
[26]   Phase I Trial of Gemcitabine Dose Escalation with Concurrent Radiotherapy for Patients with Locally Advanced Pancreatic Cancer [J].
Nishida, Tsutomu ;
Tsutsui, Shusaku ;
Yamamoto, Katsumi ;
Konishi, Koji ;
Hayashi, Yoshito ;
Iijima, Hideki ;
Tsujii, Masahiko ;
Takeda, Yutaka ;
Kitagawa, Toru ;
Yoshioka, Yasuo ;
Inoue, Takehiro ;
Hayashi, Norio .
PANCREATOLOGY, 2010, 10 (01) :60-65
[27]   Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival [J].
Woeste, Matthew R. ;
Wilson, Khaleel D. ;
Kruse, Edward J. ;
Weiss, Matthew J. ;
Christein, John D. ;
White, Rebekah R. ;
Martin, Robert C. G. .
FRONTIERS IN ONCOLOGY, 2022, 11
[28]   Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer [J].
Leung, Henry W. C. ;
Chan, Agnes L. F. ;
Muo, Chih-Hsin .
CLINICAL THERAPEUTICS, 2016, 38 (05) :1174-1183
[29]   Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial [J].
Loehrer, Patrick J., Sr. ;
Feng, Yang ;
Cardenes, Higinia ;
Wagner, Lynne ;
Brell, Joanna M. ;
Cella, David ;
Flynn, Patrick ;
Ramanathan, Ramesh K. ;
Crane, Christopher H. ;
Alberts, Steven R. ;
Benson, Al B., III .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) :4105-4112
[30]   Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis [J].
He, Chaobin ;
Wang, Jun ;
Sun, Shuxin ;
Zhang, Yu ;
Lin, Xiaojun ;
Lao, Xiangming ;
Cui, Bokang ;
Li, Shengping .
BMC CANCER, 2019, 19 (1)